Capricor Therapeutics logo
Capricor Therapeutics
CAPR | NASDAQ
Chart Builder DCF Calculator
$8.30
-$1.23 (-12.91%)
At close: Nov 16, 2026, 4:00 PM ET
$8.17
-$0.13 (-1.57%)
After-hours: Nov 16, 2026, 7:56 PM ET

Capricor Therapeutics Company Profile

Company profile explained

Company Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Key Executives

Name Position
Linda Marbán Co-Founder, President, Chief Executive Officer & Director
Anthony J. Bergmann Chief Financial Officer & Corporate Treasurer
Frank Isaac Litvack FACC Executive Chairman of the Board
Karen G. Krasney Executive Vice President, General Counsel & Secretary
Kristi A. H. Elliott Chief Operating & Science Officer
Mark Awadalla Chief Development Officer
Michael Maurer Chief Commercial Officer
Micheal Binks Chief Medical Officer
Minghao Sun Senior Vice President of Quality Control, Research & Product Development
Nathaniel Hogan Director of Biostatistics of Capricor Therapeutics
Capricor Therapeutics
Capricor Therapeutics logo
Country United States
IPO Date Feb 13, 2007
Industry Biotechnology
Sector Healthcare
Employees 231
CEO Linda Marbán

Contact Details

10865 Road to the Cure San Diego, California 92121 United States

Stock Details

Ticker Symbol CAPR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001133869
CUSIP Number 14070B309
ISIN Number US14070B3096
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.